Investigating how racial and social factors affect bladder cancer outcomes.
Official title: Racial and social contextual factors in relation to epigenome and bladder cancer outcome.
Funded at Baylor College of Medicine · NIH-10932938 · Data updated 2026-11-12
This study is looking at how race and social factors affect bladder cancer and aims to improve treatment and support for underserved communities, especially for minority patients, by bringing together experts from Baylor College of Medicine and Texas Southern University.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $36,264 |
| NIH project number | 5P20CA284971-02 |
| Project ID | NIH-10932938 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include African American individuals diagnosed with bladder cancer or those at risk due to social and racial factors.
✕Less likely to help
Patients who do not identify as part of the targeted underserved populations or those with other types of cancer may not receive benefit from this research.
What this research studies
This research focuses on understanding the impact of racial and social contextual factors on the epigenome and outcomes for patients with bladder cancer. It aims to strengthen collaboration between Baylor College of Medicine and Texas Southern University to address cancer health disparities, particularly in underserved populations. The project will develop a cancer research program that emphasizes community engagement and education, targeting predominantly minority populations to improve access to treatment and outcomes. By leveraging the expertise of both institutions, the research seeks to create a robust infrastructure for addressing these disparities.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes and access to care for bladder cancer patients from underserved communities.
How similar studies have gone: Other research has shown success in addressing cancer health disparities through community engagement and targeted interventions, indicating that this approach has potential for meaningful impact.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Putluri, Nagireddy — Baylor College of Medicine
- Study coordinator: Putluri, Nagireddy
Related research
Other NIH-funded projects on the same topics.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Understanding why bladder cancer spreads and resists treatment
This grant studies how advanced bladder cancer changes and spreads across the body, aiming to uncover why it’s hard to treat.
-
Molecular clues to bladder cancer cell changes and therapy response
This NIH grant looks at how bladder cancer cells change their identity and how that affects response to treatment, with a focus on aggressive neuroendocrine variants.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.